0000000000022052

AUTHOR

Ori Staszewski

0000-0002-0579-6701

showing 4 related works from this author

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort

2020

PURPOSE The HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy. PATIENTS AND METHODS From 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided i…

OncologyMaleCancer ResearchMedizinradiotherapy [Medulloblastoma]Neuropsychological Testsadverse effects [Cranial Irradiation]Craniospinal Irradiation0302 clinical medicinemortality [Cerebellar Neoplasms]drug therapy [Medulloblastoma]Early childhoodProspective Studiesddc:618Systemic chemotherapyCerebellar Neoplasms / mortality3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolMedulloblastoma / radiotherapyFemalemortality [Medulloblastoma]medicine.medical_specialtyCerebellar Neoplasms / drug therapyCerebellar Neoplasms / radiotherapyMEDLINEMedulloblastoma / drug therapyadministration & dosage [Methotrexate]03 medical and health sciencesInternal medicinedrug therapy [Cerebellar Neoplasms]medicineHumansddc:610Cerebellar NeoplasmsMedulloblastomaCranial Irradiation / adverse effectsbusiness.industryEditorialsInfantMethotrexate / administration & dosageDNA Methylationmedicine.diseaseClinical trialMethotrexateMedulloblastoma / mortalityradiotherapy [Cerebellar Neoplasms]Cranial IrradiationbusinessValidation cohort030217 neurology & neurosurgeryMedulloblastoma
researchProduct

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT

2020

Abstract OBJECTIVE To avoid craniospinal irradiation (CSI) in children younger than four years with non-metastatic medulloblastoma by chemotherapy, intraventricular methotrexate and risk-adapted local radiotherapy. PATIENTS AND METHODS Eighty-seven patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for non-response or progression. After 2006, local radiotherapy was introduced for non-responders or classic (CMB), anaplastic or large-cell medulloblastoma (LCA). Infantile SHH-activated medulloblastomas (SHH_INF) were subdivided by DNA-methylation profiling. Survival in SHH_INF subtypes were also assessed in a validation cohort (n=71). RESULT…

MedulloblastomaOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.disease3. Good healthClinical trialOncologyInternal medicinemedicineNon metastaticMedulloblastoma (Clinical)AcademicSubjects/MED00300AcademicSubjects/MED00310Neurology (clinical)Early childhoodbusinessValidation cohortNeuro-Oncology
researchProduct

Kinetics of gamma-H2AX focus formation upon treatment of cells with UV light and alkylating agents.

2008

Histone H2AX is rapidly phosphorylated in response to DNA double-strand breaks (DSBs) induced by ionizing radiation (IR). Here we show that DNA damage induced by alkylating agents [methyl methanesulfonate (MMS) and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)] and ultraviolet light (UV-C) leads to a dose and time dependent accumulation of phosphorylated H2AX (gamma-H2AX). Time course experiments revealed that the number of gamma-H2AX foci reached peak levels 8 hr after MMS or MNNG treatment and declined to almost control values within 24 hr after exposure. Upon UV-C treatment, a biphasic response was observed with a maximum 12 hr after treatment. In 43-3B cells deficient in nucleotide excisi…

Alkylating AgentsMethylnitronitrosoguanidineTime FactorsDNA RepairEpidemiologyDNA damageMethylnitronitrosoguanidineDNA repairUltraviolet RayscellsHealth Toxicology and MutagenesisFluorescent Antibody TechniqueCHO CellsBiologyenvironment and public healthHistoneschemistry.chemical_compoundCricetulusCricetinaeUltraviolet lightAnimalsPhosphorylationGenetics (clinical)DNA replicationMethyl MethanesulfonateMolecular biologyMethyl methanesulfonateenzymes and coenzymes (carbohydrates)KineticschemistryBiochemistrybiological phenomena cell phenomena and immunityDNANucleotide excision repairDNA DamageEnvironmental and molecular mutagenesis
researchProduct

Host microbiota constantly control maturation and function of microglia in the CNS.

2015

As the tissue macrophages of the CNS, microglia are critically involved in diseases of the CNS. However, it remains unknown what controls their maturation and activation under homeostatic conditions. We observed substantial contributions of the host microbiota to microglia homeostasis, as germ-free (GF) mice displayed global defects in microglia with altered cell proportions and an immature phenotype, leading to impaired innate immune responses. Temporal eradication of host microbiota severely changed microglia properties. Limited microbiota complexity also resulted in defective microglia. In contrast, recolonization with a complex microbiota partially restored microglia features. We determ…

Central Nervous SystemMaleCellGut–brain axis610 Medicine & healthBiologydigestive systemReceptors G-Protein-CoupledMiceImmunitymedicineAnimalsHomeostasis10239 Institute of Laboratory Animal ScienceReceptorInnate immune systemMicrogliaGeneral NeuroscienceMicrobiota2800 General NeuroscienceFatty Acids VolatilePhenotypeImmunity InnateMice Inbred C57BLmedicine.anatomical_structurenervous systemImmunology570 Life sciences; biology590 Animals (Zoology)FemaleMicrogliaNeuroscienceHomeostasisNature neuroscience
researchProduct